<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20199" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cyclophosphamide</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ogino</surname>
            <given-names>Mari H.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tadi</surname>
            <given-names>Prasanna</given-names>
          </name>
          <aff>Asram Medical College, Eluru, India</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mari Ogino declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prasanna Tadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20199.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Cyclophosphamide is a medication primarily used in the management and treatment of neoplasms, including multiple myeloma, sarcoma, and breast cancer. Cyclophosphamide is a nitrogen mustard that exerts its anti-neoplastic effects through alkylation. This activity reviews the indications, contraindications, mechanism of action, and other key factors of cyclophosphamide as a valuable agent in the treatment and management of neoplastic diseases by an interprofessional team. There is also a discussion of cyclophosphamide use in the management of severe multiple sclerosis.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action and administration of cyclophosphamide.</p></list-item><list-item><p>Describe the adverse effects and contraindications of cyclophosphamide.</p></list-item><list-item><p>Review the appropriate monitoring and toxicity of cyclophosphamide.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to advance cyclophosphamide and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20199&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20199">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20199.s2" sec-type="Indications">
        <title>Indications</title>
        <p>According to the FDA, cyclophosphamide is mainly indicated for use in the treatment of malignant lymphomas stages III and IV, as designated by the Ann Arbor staging system. These may include Hodgkin and Non-Hodgkin lymphoma, lymphocytic lymphoma, small lymphocytic lymphoma, Burkitt lymphoma, and multiple myeloma.<xref ref-type="bibr" rid="article-20199.r1">[1]</xref><xref ref-type="bibr" rid="article-20199.r2">[2]</xref></p>
        <p>Other FDA approved indications of cyclophosphamide include use in the treatment of breast cancer, disseminated neuroblastomas, retinoblastoma, minimal change nephrotic syndrome in pediatric patients, and ovarian adenocarcinomas. As an effective immunosuppressive agent, cyclophosphamide multiple studies have found cyclophosphamide useful in the treatment of autoimmune diseases such as multiple sclerosis. Cyclophosphamide has also been prescribed pretransplant as an immunosuppressant to prevent transplant rejection and graft-vs-host complications.<xref ref-type="bibr" rid="article-20199.r3">[3]</xref><xref ref-type="bibr" rid="article-20199.r4">[4]</xref></p>
      </sec>
      <sec id="article-20199.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Cyclophosphamide is a type of nitrogen mustard drug which exerts its effects through the alkylation of DNA. The drug is not cell-cycle phase-specific and metabolizes to an active form capable of inhibiting protein synthesis through DNA and RNA crosslinking. <xref ref-type="bibr" rid="article-20199.r1">[1]</xref><xref ref-type="bibr" rid="article-20199.r2">[2]</xref></p>
        <p>The majority of the antineoplastic effects of cyclophosphamide are due to the phosphoramide mustard formed from the metabolism of the drug by liver enzymes like cytochrome P-450. Hepatic enzymes first convert cyclophosphamide to hydroxycyclophosphamide and then subsequently metabolized to aldophosphamide. Aldophosphamide is cleaved to the active alkylating agent phosphoramide mustard and acrolein. The phosphoramide metabolite forms cross-linkages within and between adjacent DNA strands at the guanine N-7 position. These modifications are permanent and eventually lead to programmed cell death.<xref ref-type="bibr" rid="article-20199.r4">[4]</xref> Acrolein has no antitumor activity but is the principal-agent responsible for the manifestation of hemorrhagic cystitis.</p>
        <p>In addition to antimitotic and antineoplastic effects, cyclophosphamide has immunosuppressive effects and selectivity for T cells. High-dose cyclophosphamide is used in eradication therapy of malignant hematopoietic cells, while lower dosages have shown merit for use in selective immunomodulation of regulatory T cells. The drug decreases the secretion of interferon-gamma and IL-12 while increasing the secretion of Th2 cytokines like IL-4 and IL-10 in the CSF and peripheral blood.<xref ref-type="bibr" rid="article-20199.r5">[5]</xref><xref ref-type="bibr" rid="article-20199.r6">[6]</xref> Due to these effects, cyclophosphamide is considered as a valuable addition to tumor vaccination protocols, post-transplant alloreactivity management, and the treatment of immune-mediated conditions and some forms of vasculitis.<xref ref-type="bibr" rid="article-20199.r7">[7]</xref><xref ref-type="bibr" rid="article-20199.r1">[1]</xref><xref ref-type="bibr" rid="article-20199.r2">[2]</xref>While the precise mechanism with which cyclophosphamide exerts its immunomodulatory effects are not completely clear, several studies have suggested a few probable modes of action. These include the elimination of regulatory T cells in na&#x000ef;ve or malignant host cells, the induction of T cell growth factors like type I interferons, and preconditioning host cells for donor T cells, thus reducing alloreactivity.<xref ref-type="bibr" rid="article-20199.r5">[5]</xref><xref ref-type="bibr" rid="article-20199.r7">[7]</xref><xref ref-type="bibr" rid="article-20199.r6">[6]</xref></p>
      </sec>
      <sec id="article-20199.s4" sec-type="Administration">
        <title>Administration</title>
        <p>In the treatment of a variety of malignancies, clinicians use cyclophosphamide in combination with other chemotherapeutic agents. It is often included in standard treatment regimens for Hodgkin and non-Hodgkin lymphoma as a component of CHOP along with hydroxydaunorubicin, oncovin, and prednisone. If the malignancy has B-cell involvement, rituximab, and an anti-CD-20 monoclonal antibody, it is added to the CHOP regimen (called R-CHOP).<xref ref-type="bibr" rid="article-20199.r5">[5]</xref><xref ref-type="bibr" rid="article-20199.r8">[8]</xref><xref ref-type="bibr" rid="article-20199.r9">[9]</xref>Cyclophosphamide has also been used in combination with corticosteroids in the treatment of multiple myeloma, chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma, neuroblastoma, retinoblastoma, small cell lung cancer, and various types of sarcoma. As cyclophosphamide exerts immunosuppressive properties in addition to its anti-neoplastic effects, it is indicated in the management of other immune conditions such as severe multiple sclerosis and nephrotic syndrome.<xref ref-type="bibr" rid="article-20199.r10">[10]</xref><xref ref-type="bibr" rid="article-20199.r11">[11]</xref></p>
        <p>Cyclophosphamide is often orally administered, and the length of treatment and dosage depends upon individual factors such as metabolism, drug interactions, body mass, and age of the patient. There are standard guidelines available for the appropriate dosage and indications depending upon the goal of treatment. The general recommendation for patients without hematological deficiencies is an induction dose of IV cyclophosphamide of 40&#x000a0;to 50 mg/kg divided into dosages over 2&#x000a0;to 5 days. The maintenance dosage is dependent upon individual tolerance but is generally 1&#x000a0;to 5 mg/kg taken orally every day. A daily oral dose of 2&#x000a0;to 3 mg/kg is recommended for pediatric patients. It should not be taken for more than 90 days to avoid hemorrhagic cystitis and sterility risk in males. The recommendation for the oral formulation is that it be taken at the same time every day, usually in the morning, with liquid. If GI irritation is noted, the tablet can be taken with food.<xref ref-type="bibr" rid="article-20199.r10">[10]</xref><xref ref-type="bibr" rid="article-20199.r4">[4]</xref>While taking cyclophosphamide, an adequate intake of fluids is necessary to precipitate diuresis to reduce the risk of urinary tract side effects. To avoid the side effect of hemorrhagic cystitis, maintain a minimum urinary output of 100 mL/hr during therapy.<xref ref-type="bibr" rid="article-20199.r9">[9]</xref></p>
        <p>Mesna is a prophylactic cytoprotective drug administered orally or by IV to reduce the effects of hemorrhagic cystitis in patients treated with high-dose cyclophosphamide or ifosfamide. The recommended dosage of Mesna is generally as a fractionated dosing schedule of three IV bolus injections of 240 mg per meter cubed every 4 hours.<xref ref-type="bibr" rid="article-20199.r3">[3]</xref><xref ref-type="bibr" rid="article-20199.r4">[4]</xref></p>
      </sec>
      <sec id="article-20199.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The main areas of concern regarding the adverse side effects of cyclophosphamide are associated with bladder and gonadal toxicity. Common adverse side effects reported in several studies and clinical trials involving the use of cyclophosphamide include hemorrhagic cystitis, amenorrhea, myelosuppression, alopecia, and spells of nausea and vomiting. <xref ref-type="bibr" rid="article-20199.r12">[12]</xref><xref ref-type="bibr" rid="article-20199.r13">[13]</xref><xref ref-type="bibr" rid="article-20199.r2">[2]</xref>Chronic or recurrent hemorrhagic cystitis is a side effect of particular clinical significance and may arise from the use of cyclophosphamide without adequate hydration or concurrent administration of mesna. The limiting factor in cyclophosphamide dosage in the treatment of neoplasms and immune-inflammatory conditions is urinary tract toxicity.&#x000a0; The severity of hemorrhagic cystitis may vary from light pinkish to exsanguinating hemorrhage. Other urinary tract symptoms include increased urinary frequency and urgency due to urinary clot retention, nocturia, and dysuria.<xref ref-type="bibr" rid="article-20199.r12">[12]</xref><xref ref-type="bibr" rid="article-20199.r7">[7]</xref><xref ref-type="bibr" rid="article-20199.r3">[3]</xref>As previously outlined, acrolein is the principal-agent involved in the precipitation of hemorrhagic cystitis. The metabolite causes heightened vascular fragility and dilatation, irritation of the bladder mucosa, the release of pro-inflammatory mediators like tumor necrosis factor-alpha, IL-1 beta, and endogenous nitric oxide leading to hemorrhage. Prolonged exposure to acrolein may increase the severity of hemorrhagic cystitis. Due to the dose and time-dependent nature of the severity of this symptom, th recommendation is that the patient intake adequate fluids to force diuresis and reduce exposure of urothelium to acrolein. Continuous bladder irrigation and mesna use are also helpful in the management of drug-induced hemorrhagic cystitis.<xref ref-type="bibr" rid="article-20199.r5">[5]</xref><xref ref-type="bibr" rid="article-20199.r12">[12]</xref><xref ref-type="bibr" rid="article-20199.r6">[6]</xref></p>
        <p>Cyclophosphamide can cause myelosuppression leading to the development of sepsis and septic shock. Antibiotic therapy and additional surveillance may be warranted at the discretion of the treatment team.There are also reports of cardiotoxicity, pulmonary toxicity, veno-occlusive liver disease, and secondary malignancies in some cases of cyclophosphamide use. Myocarditis, pericardial effusion with cardiac tamponade, pneumonitis, and respiratory failure are possible risks. Higher dosages of cyclophosphamide are associated with a greater incidence of these side effects and increased mortality.<xref ref-type="bibr" rid="article-20199.r13">[13]</xref><xref ref-type="bibr" rid="article-20199.r10">[10]</xref><xref ref-type="bibr" rid="article-20199.r2">[2]</xref></p>
        <p>The alkylating effects of cyclophosphamide may also affect the processes of oogenesis and spermatogenesis, leading to sterility in both sexes. The risk of sterility of time and dose-dependent and is irreversible in some patients. Sterility may manifest as amenorrhea in women and testicular atrophy in men. Patients should receive adequate education on the risks of infertility before initiation of cyclophosphamide therapy.<xref ref-type="bibr" rid="article-20199.r12">[12]</xref><xref ref-type="bibr" rid="article-20199.r7">[7]</xref></p>
      </sec>
      <sec id="article-20199.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>As with any drug, the use of cyclophosphamide is not recommended in patients with allergies or hypersensitivity reactions to the drug or any of its metabolites. Deaths from anaphylactic reactions, as well as adverse interactions with other chemotherapy drugs like busulfan or chlorambucil, have been reported.Patients with urinary flow obstructive conditions should not take cyclophosphamide due to an increased risk of developing hemorrhagic clot retention.<xref ref-type="bibr" rid="article-20199.r12">[12]</xref><xref ref-type="bibr" rid="article-20199.r10">[10]</xref><xref ref-type="bibr" rid="article-20199.r2">[2]</xref><xref ref-type="bibr" rid="article-20199.r14">[14]</xref></p>
        <p>Pregnant or nursing women should not take cyclophosphamide as the use of the drug has been associated with embryo-fetal toxicity. Cyclophosphamide is present in breast milk, and exposure may cause congenital disabilities, delayed development, and fetal death. It is a strong recommendation that female patients receiving treatment with cyclophosphamide avoid pregnancy during treatment and use contraceptive measures during treatment and up to a full year following completion of treatment.<xref ref-type="bibr" rid="article-20199.r12">[12]</xref><xref ref-type="bibr" rid="article-20199.r7">[7]</xref><xref ref-type="bibr" rid="article-20199.r13">[13]</xref></p>
      </sec>
      <sec id="article-20199.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The monitoring of complete blood counts in patients is an essential part of the management of cyclophosphamide toxicity. As cyclophosphamide can cause myelosuppression, it should not be used in patients with lab values of neutrophils of 1500/mm^3 or less and platelets less than 50000/mm^3. CBC values should be monitored in addition to the administration of G-CSF to reduce the effects of neutropenia and infection risk.<xref ref-type="bibr" rid="article-20199.r4">[4]</xref><xref ref-type="bibr" rid="article-20199.r15">[15]</xref><xref ref-type="bibr" rid="article-20199.r16">[16]</xref>Before the induction of cyclophosphamide treatment, any urinary obstructions should be corrected or excluded. Urinalysis is also a recommendation to evaluate for the presence of hematuria, proteinuria, or bacterial infections. Patients also require monitoring for signs and symptoms of cardiotoxicity, pulmonary toxicity, and history of pre-existing cardiac disease. These tests may include tests for cholesterol, lipids, and triglycerides. The gold-standard test is generally considered to be an angiogram taken during cardiac catheterization or non-invasively via computed tomography.<xref ref-type="bibr" rid="article-20199.r5">[5]</xref><xref ref-type="bibr" rid="article-20199.r12">[12]</xref><xref ref-type="bibr" rid="article-20199.r13">[13]</xref><xref ref-type="bibr" rid="article-20199.r17">[17]</xref><xref ref-type="bibr" rid="article-20199.r14">[14]</xref></p>
        <p>Patients experiencing severe symptoms of cyclophosphamide toxicity may be taken off the medication or have their dose reduced by their physician.<xref ref-type="bibr" rid="article-20199.r12">[12]</xref><xref ref-type="bibr" rid="article-20199.r18">[18]</xref><xref ref-type="bibr" rid="article-20199.r3">[3]</xref><xref ref-type="bibr" rid="article-20199.r16">[16]</xref></p>
      </sec>
      <sec id="article-20199.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Clinicians need to consider possible side effects, interactions, and associated toxicities should before administering cyclophosphamide. As an immunosuppressive agent, cyclophosphamide toxicity correlates with the development of leukopenia, thrombocytopenia, and anemia. These conditions may lead to the occurrence of recurrent infections and may interfere with wound healing. Other symptoms of cyclophosphamide toxicity include GI disturbances, alopecia, hemorrhagic cystitis, renal tubular necrosis, infertility, pulmonary fibrosis, and cardiotoxicity. The manifestation of cyclophosphamide toxicity becomes aggravated by concurrent use of phenobarbital, other myelosuppressives, radiation, and succinylcholine.<xref ref-type="bibr" rid="article-20199.r19">[19]</xref><xref ref-type="bibr" rid="article-20199.r20">[20]</xref></p>
        <p>To minimize the negative effects of cyclophosphamide toxicity, recommendations include monitoring the patient&#x02019;s hematologic profile and modification of treatment as needed. Patients should maintain adequate hydration, and mesna can be prescribed as prophylaxis against the development of hemorrhagic cystitis. If overdose is suspected, the patient or caregiver must seek emergency medical attention immediately.<xref ref-type="bibr" rid="article-20199.r20">[20]</xref></p>
      </sec>
      <sec id="article-20199.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>In the development of professional health care delivery, the ability of interprofessional health care providers to work as a cohesive unit has been proven to increase the quality of patient care and increase positive prognostic outcomes. This paradigm is achieved through integrated patient-centered care, sharing of values, communication, and a clear definition of interprofessional responsibilities.<xref ref-type="bibr" rid="article-20199.r21">[21]</xref><xref ref-type="bibr" rid="article-20199.r22">[22]</xref></p>
        <p>In the modern health care environment, patients rely on effective teamwork within a team of health professionals. This methodology should include primary care providers, oncologists, specialty care nurses, and oncologic pharmacists. Effective communication minimizes errors and potential adverse events. Various studies on effective leadership and team development have supported Tuckman&#x02019;s stages of group development. In this model, a team undergoes four stages: forming, storming, norming, and performing. Passing through all of these stages is both necessary and inevitable for an effective team to form. Following this process, the members of the team are better able to assess their roles and the roles of others on the team. Each member possesses specialized skills and knowledge complementary to the others, allowing for heightened patient care.<xref ref-type="bibr" rid="article-20199.r23">[23]</xref></p>
        <p>This coordination is key in the appropriate use of cyclophosphamide. Adhering to the Team-Based Competencies set forth by the Interprofessional Education Collaborative, including honesty, discipline, and mutual goals, the healthcare team, is better able to assess the appropriate management of cyclophosphamide use. On an organizational level, enhanced teamwork can lead to reduced time and costs associated with hospitalizations, reduced unexpected admissions, and increased ease of access to services. From a patient&#x02019;s perspective, effective teamwork means increased satisfaction with care, improved prognosis, and a reduction in medical error.<xref ref-type="bibr" rid="article-20199.r22">[22]</xref> [Level 1]</p>
        <p>Interprofessional team dynamics in using cyclophosphamide include the prescriber deciding it is the appropriate agent for the patient, but that is only the beginning. A board-certified oncology pharmacist should be consulted regarding potential drug interactions, appropriate dosing, and have involvement in the ongoing monitoring of the patient. Once on the drug, oncology specialty nurses should have involvement in monitoring the patient for treatment progress as well as adverse drug reactions and can reach out to the oncology pharmacist and/or the oncologist as appropriate. These interprofessional examples will result in better outcomes with cyclophosphamide. [Level 5]</p>
      </sec>
      <sec id="article-20199.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20199&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20199">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20199/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20199">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20199.s11">
        <title>References</title>
        <ref id="article-20199.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mills</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Chess-Williams</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McDermott</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Novel insights into the mechanism of cyclophosphamide-induced bladder toxicity: chloroacetaldehyde's contribution to urothelial dysfunction in vitro.</article-title>
            <source>Arch Toxicol</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>93</volume>
            <issue>11</issue>
            <fpage>3291</fpage>
            <page-range>3291-3303</page-range>
            <pub-id pub-id-type="pmid">31598736</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20199.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Korkmaz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Topal</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Oter</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation.</article-title>
            <source>Cell Biol Toxicol</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>303</fpage>
            <page-range>303-12</page-range>
            <pub-id pub-id-type="pmid">17225077</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20199.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Emadi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Brodsky</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Cyclophosphamide and cancer: golden anniversary.</article-title>
            <source>Nat Rev Clin Oncol</source>
            <year>2009</year>
            <month>Nov</month>
            <volume>6</volume>
            <issue>11</issue>
            <fpage>638</fpage>
            <page-range>638-47</page-range>
            <pub-id pub-id-type="pmid">19786984</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20199.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Colvin</surname>
                <given-names>OM</given-names>
              </name>
            </person-group>
            <article-title>An overview of cyclophosphamide development and clinical applications.</article-title>
            <source>Curr Pharm Des</source>
            <year>1999</year>
            <month>Aug</month>
            <volume>5</volume>
            <issue>8</issue>
            <fpage>555</fpage>
            <page-range>555-60</page-range>
            <pub-id pub-id-type="pmid">10469891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20199.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chatelanat</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Van Delden</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Adler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Guerne</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Nendaz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Serratrice</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Risk factors and prophylaxis of Pneumocystis jirovecii pneumonia in HIV-negative patients].</article-title>
            <source>Rev Med Suisse</source>
            <year>2018</year>
            <month>Oct</month>
            <day>17</day>
            <volume>14</volume>
            <issue>623</issue>
            <fpage>1829</fpage>
            <page-range>1829-1833</page-range>
            <pub-id pub-id-type="pmid">30329227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20199.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahlmann</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hempel</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy.</article-title>
            <source>Cancer Chemother Pharmacol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>78</volume>
            <issue>4</issue>
            <fpage>661</fpage>
            <page-range>661-71</page-range>
            <pub-id pub-id-type="pmid">27646791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20199.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cavallasca</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Maliandi</surname>
                <given-names>Mdel R</given-names>
              </name>
              <name>
                <surname>Contini</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Fernandez de Carrera</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Musuruana</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Severe infections in patients with autoimmune diseases treated with cyclophosphamide.</article-title>
            <source>Reumatol Clin</source>
            <year>2015</year>
            <season>Jul-Aug</season>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>221</fpage>
            <page-range>221-3</page-range>
            <pub-id pub-id-type="pmid">25455720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20199.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nishimura</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Onoe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sakai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Arase</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Soyama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hashimoto</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Miki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tane</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hirokaga</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Safety and Relative Dose Intensity of Dose-dense Doxorubicin and Cyclophosphamide Followed by Dose-dense Paclitaxel.</article-title>
            <source>Anticancer Res</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>39</volume>
            <issue>8</issue>
            <fpage>4379</fpage>
            <page-range>4379-4383</page-range>
            <pub-id pub-id-type="pmid">31366533</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20199.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hiddemann</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kneba</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dreyling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schmitz</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lengfelder</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schmits</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Reiser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Metzner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Harder</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hegewisch-Becker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kropff</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reis</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Freund</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>W&#x000f6;rmann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Planker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schimke</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Eimermacher</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tr&#x000fc;mper</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Aldaoud</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Parwaresch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Unterhalt</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group.</article-title>
            <source>Blood</source>
            <year>2005</year>
            <month>Dec</month>
            <day>01</day>
            <volume>106</volume>
            <issue>12</issue>
            <fpage>3725</fpage>
            <page-range>3725-32</page-range>
            <pub-id pub-id-type="pmid">16123223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20199.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Atilla</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ate&#x0015f;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Uslu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ataca Atilla</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dolap&#x000e7;&#x00131;</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Tekeli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Top&#x000e7;uo&#x0011f;lu</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Prospective Analysis of Hemorrhagic Cystitis and BK Viremia in Allogeneic Hematopoietic Stem Cell Transplantation.</article-title>
            <source>Turk J Haematol</source>
            <year>2020</year>
            <month>Aug</month>
            <day>28</day>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>186</fpage>
            <page-range>186-192</page-range>
            <pub-id pub-id-type="pmid">31852035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20199.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siddhartha</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vijay</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>R-CHOP versus R-CVP in the treatment of follicular lymphoma: a meta-analysis and critical appraisal of current literature.</article-title>
            <source>J Hematol Oncol</source>
            <year>2009</year>
            <month>Mar</month>
            <day>24</day>
            <volume>2</volume>
            <fpage>14</fpage>
            <pub-id pub-id-type="pmid">19309523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20199.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Adler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>F&#x000f6;rger</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Villiger</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Cyclophosphamide: As bad as its reputation? Long-term single centre experience of cyclophosphamide side effects in the treatment of systemic autoimmune diseases.</article-title>
            <source>Swiss Med Wkly</source>
            <year>2014</year>
            <volume>144</volume>
            <fpage>w14030</fpage>
            <pub-id pub-id-type="pmid">25341028</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20199.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lauwerys</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lef&#x000e8;bvre</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Devogelaer</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Houssiau</surname>
                <given-names>FA</given-names>
              </name>
            </person-group>
            <article-title>Side-effects of intravenous cyclophosphamide pulse therapy.</article-title>
            <source>Lupus</source>
            <year>1997</year>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>254</fpage>
            <page-range>254-7</page-range>
            <pub-id pub-id-type="pmid">9104732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20199.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tabchi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kunacheewa</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Amini</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mehta</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Bashir</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Qazilbash</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Orlowski</surname>
                <given-names>RZ</given-names>
              </name>
              <name>
                <surname>Alexanian</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Feng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Manasanch</surname>
                <given-names>EE</given-names>
              </name>
            </person-group>
            <article-title>Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.</article-title>
            <source>Clin Lymphoma Myeloma Leuk</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>19</volume>
            <issue>9</issue>
            <fpage>560</fpage>
            <page-range>560-569</page-range>
            <pub-id pub-id-type="pmid">31201134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20199.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campagne</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Onar-Thomas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gajjar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>CF</given-names>
              </name>
            </person-group>
            <article-title>Exposure-Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing.</article-title>
            <source>Clin Cancer Res</source>
            <year>2020</year>
            <month>Apr</month>
            <day>01</day>
            <volume>26</volume>
            <issue>7</issue>
            <fpage>1563</fpage>
            <page-range>1563-1573</page-range>
            <pub-id pub-id-type="pmid">31796512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20199.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gregory</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Tr&#x000fc;mper</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes?</article-title>
            <source>Ann Oncol</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>9</issue>
            <fpage>1413</fpage>
            <page-range>1413-24</page-range>
            <pub-id pub-id-type="pmid">15932900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20199.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hirshman</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Doan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Harper</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Leidig</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Purves</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>Cyclophosphamide-induced cystitis results in NLRP3-mediated inflammation in the hippocampus and symptoms of depression in rats.</article-title>
            <source>Am J Physiol Renal Physiol</source>
            <year>2020</year>
            <month>Feb</month>
            <day>01</day>
            <volume>318</volume>
            <issue>2</issue>
            <fpage>F354</fpage>
            <page-range>F354-F362</page-range>
            <pub-id pub-id-type="pmid">31869244</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20199.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Evens</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Loh</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>David</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Management of older Hodgkin lymphoma patients.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2019</year>
            <month>Dec</month>
            <day>06</day>
            <volume>2019</volume>
            <issue>1</issue>
            <fpage>233</fpage>
            <page-range>233-242</page-range>
            <pub-id pub-id-type="pmid">31808898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20199.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fraiser</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Kanekal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kehrer</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Cyclophosphamide toxicity. Characterising and avoiding the problem.</article-title>
            <source>Drugs</source>
            <year>1991</year>
            <month>Nov</month>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>781</fpage>
            <page-range>781-95</page-range>
            <pub-id pub-id-type="pmid">1723374</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20199.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmed</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Hombal</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1984</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>1115</fpage>
            <page-range>1115-26</page-range>
            <pub-id pub-id-type="pmid">6392368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20199.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nancarrow</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Booth</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ariss</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Enderby</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Roots</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Ten principles of good interdisciplinary team work.</article-title>
            <source>Hum Resour Health</source>
            <year>2013</year>
            <month>May</month>
            <day>10</day>
            <volume>11</volume>
            <fpage>19</fpage>
            <pub-id pub-id-type="pmid">23663329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20199.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pillay</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wootten</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Crowe</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Corcoran</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bowden</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Crowe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Costello</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature.</article-title>
            <source>Cancer Treat Rev</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>42</volume>
            <fpage>56</fpage>
            <page-range>56-72</page-range>
            <pub-id pub-id-type="pmid">26643552</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20199.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McMorris</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Gottlieb</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Sneden</surname>
                <given-names>GG</given-names>
              </name>
            </person-group>
            <article-title>Developmental stages in public health partnerships: a practical perspective.</article-title>
            <source>Health Promot Pract</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>219</fpage>
            <page-range>219-26</page-range>
            <pub-id pub-id-type="pmid">15855293</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
